

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/335	A1	(11) International Publication Number: WO 94/25020 (43) International Publication Date: 10 November 1994 (10.11.94)
<p>(21) International Application Number: PCT/SE94/00371</p> <p>(22) International Filing Date: 26 April 1994 (26.04.94)</p> <p>(30) Priority Data: 9301422-3 28 April 1993 (28.04.93) SE</p> <p>(71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MÅNSSON, Per [SE/SE]; Porsvågen 4, S-191 48 Sollentuna (SE). ROLFSEN, Wenche [SE/SE]; Kvarnbogatan 16, S-752 39 Uppsala (SE). WICK-STRÖM, Kerstin [SE/SE]; Sankt Johannesgatan 31A, S-752 33 Uppsala (SE).</p> <p>(74) Agents: BERGANDER, Håkan et al.; Kabi Pharmacia AB, Patent Dept., S-751 82 Uppsala (SE).</p>		<p>(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, DE, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SE, UA, US, UZ, VN; European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: METHOD AND MEANS FOR INHIBITING POSTERIOR CAPSULE OPACIFICATION</p> <p>(57) Abstract</p> <p>Use of taxol or a pharmaceutically active and ophthalmologically acceptable derivative thereof for manufacturing an intraocular composition for preventing secondary cataract after extracapsular cataract extraction with or without intraocular lens (IOL) implantation.</p>		

BEST AVAILABLE COPY

ATTORNEY DOCKET NUMBER: 10177-211-999
(Cam No. 008563-999208)
SERIAL NUMBER: 09/910,308
REFERENCE: B76

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD AND MEANS FOR INHIBITING POSTERIOR CAPSULE
OPACIFICATION.

The present invention is related to the field of ophthalmology and more specifically to a composition and its use for preventing secondary cataract, a long term complication after extracapsular cataract extraction with or without intraocular lens (IOL) implantation.

A great number of intraocular lens models have been developed and commercialised over the years and these as well as the techniques for IOL implantation have been improved so that extracapsular cataract extraction with intraocular lens implantation are nowadays well established procedures with a high success rate. Opacification of the posterior capsule in the optical axis is however still a significant long-term complication reported, within 3 to 5 years after surgery, in as much as 50% of the cases,. This condition is the result of deposition or in-growth of cells, mainly remnant lens epithelial cells (LEC) which proliferate on the posterior lens capsule resulting in blocking of incoming light. The direct consequence is the need for posterior capsulotomy, which has a comparatively high incidence (1-3%) of serious complications.

A number of different ways to prevent secondary cataract have been tested over the years, both with regard to the intraocular lens as such and the technique used in surgery. So has for instance Hoffer in US 4244060 described a lens that has a barrier ridge on the side facing the capsule wall. The intention is to create a mechanical barrier inhibiting migration of residual lens epithelial cells and their derivatives into the optical zone behind the IOL.

Administration of various types of drugs during surgery for preventing opacification is another approach that has been found to be of potential importance. Examples of such drugs are colchicine and 5-fluorouracil.

Colchicine is a mitosis-inhibiting phenanthrene derivative isolated from Colchicum autumnale. Colchicine arrests mitosis at metaphase by binding to a protein present in microtubules,

hence interfering with the structure of the mitotic spindle. The substance has been shown to be a potent inhibitor of lens epithelial cell proliferation and migration. However, colchicine has a low therapeutic index with a lot of potential side effects, including a temporary toxic effect on the optic nerve when used for preventing posterior capsule opacification in primates.

5-Fluorouracil is a potent anti mitotic drug affecting the DNA replication and is widely used in the treatment of epithelial tumours. Ruitz et al (Inhibition of posterior capsule opacification by 5-fluorouracil in rabbit; Ophthalmic Res. 22 (1990) 201-208) have also shown that this substance reduces posterior capsule opacification in vivo in rabbits.

Since 1982 subconjunctival administration of 5-fluorouracil has been utilized in patients at high risk of failure of glaucoma filtering surgery. Although beneficial effects of the substance have been clearly demonstrated, disadvantages have included corneal epithelial defects and other ocular complications.

In spite of the different approaches tested, opacification is still a considerable problem. We have now found that the substance taxol that is obtained from the bark of Western yew (Taxus brevifolia) constitutes a very promising drug candidate for preventing opacification after extracapsular cataract extraction. The substance is known to promote the formation of microtubule bundles, which deform the cytoskeleton and interfere with mitosis. Taxol is used as a broad spectrum antitumour agent in many different forms of tumours.

Chemical as well as certain therapeutic properties of taxol and some derivatives of taxol have been described in the literature, see for instance "The Chemistry of Taxol, a Clinically Useful Anticancer Agent" by Kingston et al in

Journal of Natural Products 53(1) (1990) pages 1-12. With taxol derivatives for use according to the invention is meant

functional analogues which are effective in preventing secondary cataract by inhibiting epithelial cell proliferation and migration. In the article by Kingston et al various derivatives are disclosed and these are included here by reference.

Taxol has also been tested in certain ophthalmological applications. Joseph et al (Current Eye Research 8(2) (1989) p.203-215) have suggested its potential use in glaucoma drainage surgery and taxol has also been found useful in inhibiting tractional retinal detachment in experimentally induced proliferative vitreoretinopathy in the eyes of rabbits (see Daniels et al, Graefe's Arch Clin Exp Ophthalmol 228 (1990) p.513-516). Because of the poor solubility in aqueous solution taxol was dissolved in 30% dimethylsulfoxide (DMSO).

Daniels SA et al (Ocular Toxicity of Intravitreal Taxol; J Toxicol & Ocular Toxicol 8 (1989) p 191-199) have suggested that up to about 8.5 µg of taxol in 0.1 ml of solution can safely be injected as single intravitreal doses in rabbit's eyes without causing damage to the ocular tissue.

The method of preventing opacification after extracapsular cataract extraction comprises the administration of a small amount of taxol in a single dose during surgery. The substance is administered in solid state, for instance in microcrystalline form or dissolved in an ophthalmologically acceptable medium. It is also possible to dissolve the substance in one medium, in which the solubility is good, with subsequent transfer of the dissolved substance to a carrier matrix as described below, whereby the medium used for dissolving the substance is removed. This procedure makes it possible to use as a solubilizing agent a medium which is not well suited for use inside the eye. Examples of systems for

solubilizing the active compound include alcohols like ethanol. After that the substance has been transferred to the carrier medium or matrix the solvent is removed for instance by evaporation or simply washed away.

In a first embodiment of the invention taxol or a derivative thereof is administered in a small volume, for instance 0.1 to 0.3 ml, of a viscoelastic medium of a type that is ophthalmologically acceptable, for instance aqueous solutions of hyaluronic acid or carboxymethyl cellulose, just to mention a couple of examples. The most widely used substance in this connection is Healon[®], a highly purified hyaluronic acid product from Kabi Pharmacia AB. In most cases the viscoelastic medium that has been used for facilitating the surgical procedure is removed and after this has been done the taxol-containing volume is injected into the space between the lens and the capsule wall, and the opening in the eye is closed.

In a second embodiment of the invention taxol, or a derivative thereof, is incorporated in an intraocular drug delivery system providing a slow release effect. The active substance in solid form could be coated with or encapsulated by an ophthalmologically acceptable carrier substance. Examples of systems, which are generally known for encapsulating drugs, are liposomes which are membranelike vesicles, and microspheres based on polymers of lactic and glycolic acid. A slow release system can alternatively be prepared by adding taxol or derivative thereof in dissolved form to a carrier matrix under conditions so that a desired amount of the substance is incorporated. An example of such a carrier matrix is a gel, for instance a biodegradable gel of hyaluronic acid as disclosed in EP 408731.

In a third embodiment of the invention the intraocular lens to be implanted is used as carrier for taxol or the derivative thereof, for instance adsorbed or bound to the lens surface, preferably to the haptics, or as a slow-release depot

in a hole or cavity outside the optical part of the lens surface.

In a fourth embodiment of the invention a slow release composition comprising taxol or a derivative thereof is deposited directly on the capsule tissue, under conditions so

that the composition is bound to the tissue or forms an interpenetrating network with the tissue surface layer.

In a relevant in vitro test that has been carried out, rabbit lens epithelial cells were exposed to a series of taxol solutions with various concentrations for about one week in culture. The substance was dissolved in absolute ethanol and was then diluted with the culture medium (Dulbecco's Modified Eagle Medium supplemented with Ham's F-12, antibiotics and foetal calf serum) to concentrations in the range of from 1 pg/ml to 1mg/ml. At concentrations exceeding 100 ng/ml significant reduction in cellular growth was observed, confirming the potential use of taxol and ophthalmologically active derivatives thereof for preventing secondary cataract.

The at present preferred embodiment of the invention comprises intraocular administration of taxol in microcrystalline form in an amount of about 0.005 to 5 μ g and especially 0.1 to 5 μ g, in approximately 0.1 ml of a viscoelastic medium, especially Healon®. The dose might especially in slow release systems be considerably higher, for instance up to about 25 μ g.

Claims

1. Use of taxol or a pharmaceutically active and ophthalmologically acceptable derivative thereof for manufacturing an intraocular composition for preventing secondary cataract after extracapsular cataract extraction with or without intraocular lens (IOL) implantation.
2. Use according to claim 1 whereby the composition contains up to 25 µg of taxol or the derivative thereof.
3. Use according to claim 2 wherein the composition contains from about 0.1 to 5 µg of taxol or the derivative thereof.
4. Use according to any one of claims 1 to 3 whereby taxol or the derivative thereof is in microcrystalline form.
5. Use according to any one of claims 1 to 4 whereby taxol or the derivative thereof is encapsulated in a slow release composition.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00371

A. CLASSIFICATION OF SUBJECT MATTER

IPC ~~5~~ A61K 31/335

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC ~~5~~: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, MEDLINE, EMBASE BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Graefe's Archive of Clinical and Experimental Ophthalmology, Volume 228, 1990, Stewart A. Daniels, "Taxol treatment of experimental proliferative vitreoretinopathy"	1-5
	--	
A	Ophthalmic Res, Volume 22, 1990, J.M. Ruiz, "Inhibition of Posterior Capsule Opacification by 5-Fluorouracil in Rabbits"	1-5
	--	

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15 July 1994

03 -08- 1994

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00371

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	STN, EMBASE, Accession no.93309059, Jampel H.D. et al: "Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers.", Invest. Ophthalmol. Visual Sci., (1993) 34/11 (3076-3083) ----- -----	1-5